De Lepeleire I, Van Hecken A, Verbesselt R, Tjandra-Maga T B, Buntinx A, Distlerath L, De Schepper P J
Department of Pharmacology and Clinical Pharmacology, University of Leuven, School of Medicine, Belgium.
Int J Clin Pharmacol Res. 1990;10(3):167-71.
In eight healthy male volunteers taking daily subtherapeutic doses of warfarin (mean daily dose = 4.0 mg), the addition of famotidine 40 mg once-a-day for seven days did not alter the prothrombin time profile, thrombotest coagulation time or total warfarin steady-state plasma concentration. Plasma peak concentration, time to peak concentration and area under curve for famotidine were not affected by the co-administration of warfarin. However the plasma half-life of famotidine was slightly, but statistically significantly longer (p less than 0.05) during maintenance treatment with warfarin (mean +/- s.e.m.: 2.58 +/- 0.14 h versus 2.96 +/- 0.16 h respectively).
在八名每日服用低于治疗剂量华法林（平均每日剂量 = 4.0毫克）的健康男性志愿者中，连续七天每天加用40毫克法莫替丁并未改变凝血酶原时间曲线、血栓试验凝血时间或华法林稳态血浆总浓度。华法林的合用未影响法莫替丁的血浆峰浓度、达峰时间及曲线下面积。然而，在华法林维持治疗期间，法莫替丁的血浆半衰期略有延长，但具有统计学显著性差异（p小于0.05）（平均值±标准误：分别为2.58±0.14小时和2.96±0.16小时）。
